Retatrutide

Product overview

Retatrutide is supplied by our Bangladesh facility as a lyophilised powder in sealed vials. The material is produced by solid-phase peptide synthesis, purified by preparative chromatography and lyophilised under controlled conditions.

Receptor pharmacology

In the published literature, Retatrutide is described as a synthetic peptide with agonist activity at three receptors: GLP-1, GIP and glucagon. This receptor profile is what distinguishes it from semaglutide, described as a GLP-1 receptor agonist, and from tirzepatide, described as a dual GLP-1 and GIP receptor agonist.

This section records receptor pharmacology as reported in the literature, and is provided for reference when designing in-vitro receptor-binding or cell-signalling experiments. It describes no clinical application, dosage, route of administration or therapeutic use, and no biological or clinical outcome is stated or implied.

Intended laboratory use

This product is intended exclusively as a reference material for in-vitro laboratory research, analytical method development and reagent qualification. It is not a medicine, food supplement, cosmetic or medical device.

Quality control

Each released batch is analysed by reverse-phase HPLC and documented in a Certificate of Analysis that records the batch number, test date, measured purity and the testing laboratory. Batch records and retention samples are retained for traceability.

Handling

Handle using standard laboratory practice for lyophilised peptide material. Equilibrate vials to room temperature before opening to avoid condensation. Prepare working solutions using appropriate laboratory solvents and confirm solubility for your specific assay system.